While studies have examined immune cell changes after 3 months of using a DPP-4 inhibitor (sitagliptin) in type 2 diabetes patients,[1,4] there is currently no research on the impact of a DPP-4 inhibitor on the immune system at 3 and 6 months in type 2 diabetes patients with chronic kidney disease. Here, DPP4 is linked to type 2 diabetes mellitus.